Novartis Keeps Faith That Six-Month Entresto Extension Will ‘Be Respected’
MSN’s ANDA Still Barred By Administrative Stay In US Topsy-Turvy Legal Battle
Reporting global Entresto sales of more than $7.8bn in 2024, Novartis spoke to investors on the latest legal dynamics for its best-selling product as the threat of US generic competition from MSN Laboratories continues to loom.
